Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma by unknown
BioMed CentralRadiation Oncology
ssOpen AcceResearch
Comparison of CT and integrated PET-CT based radiation therapy 
planning in patients with malignant pleural mesothelioma
Berrin Pehlivan*†1, Erkan Topkan†1, Cem Onal†1, Gul Nihal Nursal†2, 
Oznur Yuksel†1, Yemliha Dolek†1, Melek Nur Yavuz†1 and Ali Aydin Yavuz†1
Address: 1Department of Radiation Oncology, Baskent University Medical Faculty, Adana Medical and Research Center, Kisla Campus, Adana, 
Turkey and 2Department of Nuclear Medicine, Baskent University Medical Faculty, Adana Medical and Research Center, Kisla Campus, Adana, 
Turkey
Email: Berrin Pehlivan* - berrin_pehlivan@yahoo.com; Erkan Topkan - drerkantopkan@yahoo.com; Cem Onal - hcemonal@hotmail.com; 
Gul Nihal Nursal - gnnursal@yahoo.com; Oznur Yuksel - droznuryuksel@hotmail.com; Yemliha Dolek - yemliha2@hotmail.com; 
Melek Nur Yavuz - myavuz@baskent-adn.edu.tr; Ali Aydin Yavuz - ayavuz@baskent-adn.edu.tr
* Corresponding author    †Equal contributors
Abstract
Background: When combined with adequate tumoricidal doses, accurate target volume
delineation remains to be the one of the most important predictive factors for radiotherapy (RT)
success in locally advanced or medically inoperable malignant pleural mesothelioma (MPM) patients.
Recently, 18-fluorodeoxyglucose positron emission tomography (PET) has demonstrated
significant improvements in diagnosis and accurate staging of MPM. However, role of additional PET
data has not been studied in RT planning (RTP) of patients with inoperable MPM or in those who
refuse surgery. Therefore, we planned to compare CT with co-registered PET-CT as the basis for
delineating target volumes in these patients group.
Methods: Retrospectively, the CT and co-registered PET-CT data of 13 patients with
histologically proven MPM were utilized to delineate target volumes separately. For each patient,
target volumes (gross tumor volume [GTV], clinical target volume [CTV], and planning target
volume [PTV]) were defined using the CT and PET-CT fusion data sets. The PTV was measured in
two ways: PTV1 was CTV plus a 1-cm margin, and PTV2 was GTV plus a 1-cm margin. We analyzed
differences in target volumes.
Results: In 12 of 13 patients, compared to CT-based delineation, PET-CT-based delineation
resulted in a statistically significant decrease in the mean GTV, CTV, PTV1, and PTV2. In these 12
patients, mean GTV decreased by 47.1% ± 28.4%, mean CTV decreased by 38.7% ± 24.7%, mean
PTV1 decreased by 31.1% ± 23.1%, and mean PTV2 decreased by 40.0% ± 24.0%. In 4 of 13 patients,
hilar lymph nodes were identified by PET-CT that was not identified by CT alone, changing the
nodal status of tumor staging in those patients.
Conclusion: This study demonstrated the usefulness of PET-CT-based target volume delineation
in patients with MPM. Co-registration of PET and CT information reduces the likelihood of
geographic misses, and additionally, significant reductions observed in target volumes may
potentially allow escalation of RT dose beyond conventional limits potential clinical benefits in
tumor control rates, which needs to be tested in future studies.
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Malignant pleural mesothelioma (MPM) is a relatively
rare but highly aggressive tumor with expected median
survival of only 9 to 17 months [1,2]. Although currently
it appears to be a rare tumor, its incidence is increasing
throughout most of the world including Turkey, where it
is epidemic in three villages of the Cappadocia region.
Also, familial forms with autosomal dominant inherit-
ance have been reported in this region [3,4].
Although there is no universally accepted standard treat-
ment for MPM, currently the EPP is the most widely pre-
ferred treatment modality. However, due to significant
procedure related modality and mortality 85 to 90% of
patients are not eligible for this aggressive procedure [5,6].
In this context, radiation therapy (RT) as the sole treat-
ment in the presence or absence of concurrent chemother-
apy may be a good alternative in suitable patient
population. However, RT planning (RTP) for MPM is dif-
ficult due to the large, irregularly shaped area at risk, the
high doses required for local control, and the proximity of
many radiosensitive structures such as the liver, ipsilateral
kidney, heart, spinal cord, esophagus, contralateral lung,
and the ipsilateral lung itself in inoperable cases. In the
latter setting, which is a therapeutic challenge, the recent,
more sophisticated RT techniques, including intensity-
modulated radiotherapy (IMRT), image guided radiother-
apy (IGRT), and especially helical tomotherapy (HT), are
promising. However, similar with all other tumor sites,
accurate target delineation is crucial when RT is consid-
ered as the sole treatment or as a component of oncologic
treatment, and additionally when combined with ade-
quate tumoricidal doses, accurate target volume delinea-
tion remains to be the one of the most important
predictive factors for RT success in MPM.
Computed tomography (CT) is the primary imaging
modality used in staging and RT planning for MPM. Rind-
like extension of the tumor on the pleural surfaces is the
most common CT feature [7]. However, CT often fails to
accurately demonstrate transdiaphragmatic invasion and
mediastinal lymph nodes [8,9]. Recently, 18-fluorodeox-
yglucose positron emission tomography (PET) has dem-
onstrated significant improvements in diagnosis, accurate
staging, RTP, and assessment of tumor response to the
prescribed treatment in a variety of tumor sites including
the MPM [10-16]. PET imaging is based on biochemical
processes that may offer better detection of tumors even
before they become anatomically apparent. Integration of
functional PET data with the detailed anatomical infor-
mation of CT (PET-CT) has markedly increased the sensi-
tivity, specificity and accuracy of discrimination between
benign and malignant diseases, determination of tumoral
extensions in to the mediastinum, abdominal cavity or
pleural surfaces, medistinal lymph nodes or distant vis-
cera [10,17,18]. In this context, integrated PET-CT pro-
vides more information, compared with ametabolic CT or
nonanatomic PET. The high sensitivity and specificity of
PET-CT in patients with MPM have been well docu-
mented. Benard et al analyzed 28 patients with suspected
MPM and reported that specificity of PET was 100% with
sensitivity of 91% in differentiating benign and malignant
lesions [10]. Caretta et al found similar results, with accu-
racy of PET at 92% in the differential diagnosis of pleural
diseases [17]. Similarly, in their recent report Plathow et
al analyzed 54 patients with stage II and III MPM, and the
authors reported accuracy of 77% for CT, 86% for PET,
80% for Magnetic Resonance Imaging (MRI), and 100%
for PET-CT in patients with stage II disease, and accuracy
of 75% for CT, 83% for PET, 90% for MRI, and 100% for
PET-CT in patients with stage III disease [18].
To our knowledge, no studies address the role of PET-CT-
based RTP in patients with medically inoperable MPM or
in those who refuse surgery. Largely based on the afore-
mentioned data, we hypothesized that using PET-CT data
rather than CT data alone would change RT fields and pos-
sibly result in fewer geographic misses for unresected
MPM. Therefore, in the present study, we compared CT-
based and integrated PET-CT-based gross tumor volume
(GTV) delineation and its subsequent expansion to clini-
cal target volume (CTV) and planning target volume
(PTV).
Methods
Thirteen patients with histological diagnosis of MPM who
were not candidate for a curative resection due to medical
reasons or self refusal those who were treated with thora-
sic irradiation with a palliative intent are planned to be
reassessed whether the intented target volumes may have
changed if additional PET data was used in conjunction
with CT compared to CT alone. This study was largely
based on recent impressive high sensitivity and specifity
data of PET in MPM diagnosis and staging as mentioned
previously [10,17,18]. This pure delineation study proto-
col to evaluate the potential differences via implementa-
tion of PET-CT on palliative MPM cases was approved by
the institutional ethic committee. Patients' charts were
reviewed for the search of characteristics with nonmeta-
static mesothelioma classified as T2-4 and/or N0-3
according to the International Mesothelioma Interest
Group staging system [19], and no previous surgical resec-
tion.
As we acknowledged from patients' hospital records, each
patient was placed in the supine position with both arms
raised above their heads in a manner identical to treat-
ment positioning during PET-CT. The PET-CT scan was
performed in an integrated PET-CT system (Discovery-STE
8, General Electric System, Milwaukee, WI, USA). PatientsPage 2 of 7
(page number not for citation purposes)
Radiation Oncology 2009, 4:35 http://www.ro-journal.com/content/4/1/35were advised to fast for at least 6 hours before the PET
appointment. After 370 to 555 MBq (10-15 mCi) 18-
fluorodeoxyglucose was injected, patients rested for
approximately 60 minutes in a comfortable chair. Prein-
jection blood glucose levels were measured to ensure that
they were below 150 mmol/L. The patients were scanned
on a flat-panel carbon fiber composite table insert. An
enhanced CT scan from the base of the skull to the inferior
border of the pelvis was acquired with 5-mm slice thick-
ness, using a standardized protocol with 140 kV and 80
MA with contrast injection. The subsequent PET scan was
acquired from the base of the skull to the inferior border
of the pelvis as in the CT scan, using multiple-bed posi-
tion. Attenuation was corrected by using the CT images.
The processed images were displayed in coronal, trans-
verse, and saggital planes.
After image acquisition, PET-CT data sets were transferred
to our treatment planning system, Eclipse 7.5 (Varian
Medical Systems, Palo Alto, CA, USA) into DICOM RT for-
mat, and the available data was utilized for planning pur-
poses following image fusion. The CT-based and PET-CT-
based treatment planning was computed for each patient.
The target volumes were defined by the radiation oncolo-
gist (BP and checked by ET) with specific experience in
MPM cancer treatment on the CT and integrated PET-CT
images. The GTV was defined as the volume of macro-
scopic primary tumor and involved hilar and mediastinal
lymph nodes identified on the planning CT. The CTV was
created automatically with a 1-cm margin around the GTV
with respecting to the natural anatomical barriers, such as
vertebral column. The PTV1 encompassed the CTV plus a
mean 1-cm margin, and PTV2 was created with a 1-cm
margin to the GTV. All volumes were defined again on
integrated PET-CT images. Lungs (right and left sepa-
rately), liver, heart, esophagus, and kidneys (right and
left) were counted as organs at risk in each patient. We set
the window and level for the PET images according to
method previously described by Erdi et al for accurate tar-
get volume definition [20]. In this protocol, we first meas-
ured the value of the hottest pixel in the lesion and then
set the upper window level to this maximum value and set
the lower window level to 42% of the maximum level.
Statistical Analysis
On the basis of the literature, we hypothesized that inte-
gration of PET into RTP would change the target volumes
in approximately 30% of the patients. To detect such a
change with a 95% confidence interval of 5% to 55%, we
needed to enroll at least 13 patients. Statistical differences
between paired parameters from CT-based versus PET-CT-
based treatment plans were evaluated with the Wilcoxon
signed rank test. Results are expressed as mean ± standard
deviation (SD). Differences were considered statistically
significant when the two-tailed P value was less than .05.
Results
Demographic and clinical characteristics of the 13
patients are depicted in Table 1. Four of the 13 patients
were women. Median age was 50 years, with range of 38
to 74 years. In all but one patient, compared with CT-
based delineation, PET-CT-based delineation resulted in
significantly decreased mean GTV, CTV, PTV1, and PTV2
(Table 2). In these 12 patients, mean GTV decreased by
47.1% ± 28.4%, mean CTV decreased by 38.7% ± 24.7%,
mean PTV1 decreased by 31.1% ± 23.1%, and mean PTV2
decreased by 40.0% ± 24.0%. In all 12 patients the respec-
tive target volume reductions were solely due to reduced
primary tumor volumes on PET-CT fusion compared to
CT with no change in nodal disease exclusion by PET data.
In one patient, volumes were increased by PET-CT com-
pared with CT; these increases were 19%, 2%, 10% and
15% in GTV, CTV, PTV1 and PTV2, respectively. This
Table 1: Patient characteristics.
Patient # Sex Age, y ECOG Stage SUVmax SUVmean
1 Male 50 1 T4N3M0 11.5 7.5
2 Female 54 1 T3N1M0 21.8 12.5
3 Male 74 0 T1aN3M0 10.9 5.1
4 Male 38 1 T4N1M0 4.2 2.3
5 Male 43 0 T1aN2 M0 6.7 3.5
6 Male 47 0 T2N0M0 6.5 4.1
7 Male 42 0 T1aN3M0 7.2 6.9
8 Female 71 1 T1aN3M0 9.8 5.6
9 Male 46 0 T3N0M0 13.2 8.6
10 Female 64 1 T1aN2M0 7.9 4.7
11 Male 74 0 T1aN2M0 15.3 8.4
12 Male 47 1 T4N2M0 12.0 6.9
13 Female 50 0 T3N1M0 9.5 6.8
*Abbreviations: ECOG, Eastern Cooperative Oncology Group; M, distant metastasis; N, lymph-nodal disease; T, tumor extension.
Stage was determined using the International Mesothelioma Interest Group criteria.Page 3 of 7
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detection by PET data which was not appearent on CT.
In 4 of 13 patients (31%), PET-CT identified increased 18-
fluorodeoxyglucose uptake in hilar lymph nodes that did
not appear on CT, thereby changing the N stage in those 4
patients. In 3 patients (23%), PET-CT showed subdia-
phragmatic extension of the disease which did not appear
on CT. Representative images of a patient with different
GTV delineations are seen in the Figure 1 and Figure 2.
Discussion
On background of a nonexistent radiotherapeutic consen-
sus for unresected nonmetastatic MPM in the literature,
we performed a pure delineation study to evaluate the dif-
ferences via implementation of PET-CT in order to gener-
ate potential possibilities for future radiotherapy
decisions with current and coming cutting edge techno-
logic advances. The results of the current study revealed
that compared to CT, integrated PET-CT-based target vol-
ume delineation significantly reduced the GTV and its
expansions, CTV and PTV, in 12 of 13 patients and
increased target volumes in 1 patient, all together impact-
ing the importance of accurate target volume delineation
in this patients group. Additionally, we found that func-
tional PET data changed the N stage in 4 of 13 patients,
and subdiaphragmatic tumor extension was evident in
further 3 (23%) patients that was not shown by CT, which
may explain the possibility of geographic misses experi-
enced with CT-based RTP and its influence on poor out-
comes in patients with MPM.
There is currently no universally accepted standard ther-
apy for MPM. Regarding the difficulties in diagnosis, stag-
ing, and treatment, it presents a unique therapeutic
challenge. Currently, EPP with en bloc resection of the
lung, pleura, ipsilateral diaphragm, and pericardium is
the treatment of choice. However, only 10% to 15% of
patients are eligible for this extensive surgery [5,6], and
significant procedure-related morbidity and mortality
limit its use. In addition, even with EPP, R0 resection is
theoretically impossible, and microscopic or macroscopic
disease almost always remains at the resection margins.
When EPP is the sole treatment modality, locoregional
recurrence is unacceptably high, ranging from 31% to
64% [21-23]. Therefore, postoperative RT is usually indi-
cated. In a number of studies, high-dose hemithoracic RT
of 45 to 50 Gy with a boost to 54 to 60 Gy targeted to areas
at higher risk for local recurrence significantly improved
local control [24-27]. In a study by Perrot et al, only 10%
of patients developed recurrence in the ipsilateral hemith-
orax after completion of intended 60 Gy RT [24]. Simi-
larly, Rusch et al demonstrated that adjuvant
hemithoracic RT of 54 Gy following EPP improved local
control with a 13% risk of local failure [26]. However, as
was the case in our current cohort, the majority of patients
with malignant pleural mesothelioma are not good candi-
dates for curative EPP due to presence of either advanced
local disease or unfavorable medical conditions that
render them unfit for surgery.
In the setting of unresectable or medically inoperable/
patient refusal conditions, RT when applied with pallative
intent may offer good symptom control in conventional
palliative doses. However, there is strong evidence sug-
gesting better symptom and possibly loco-regional tumor
control with higher doses approaching to that is used for
curative intent. In one study, Ball et al showed that only 1
(4%) of 23 patients who received < 40 Gy achieved symp-
tomatic relief while 4 (66%) of 6 patients treated with >
40 Gy had satisfactory symptom palliation impacting the
importance of total dose even for palliative purposes [28].
Largely based on this data we planned to reassess our
patients those who were treated with an palliative
approach whether they were suitable for higher RT doses
in the range of curative 54 Gy, as these patients theorati-
cally still bear a chance for cure with higher RT doses even
in absence of EPP. However, absence of a HT unit or a
similar volumetric arc technology in our clinics signifi-
cantly limited our ability to create clinically relevant and
acceptable RTPs based on compatible pulmonary toxicity
criteria. Therefore we planned to only compare the con-
ventional CT- and PET-CT based target volume delinea-
tions which may positively impact and alter the future
RTPs either for curatively or palliatively intended
approaches in presence of HT facilities.
Despite the evident advantages offered by escalated doses
with use of 3D- conformal RT it is not usually possible to
Table 2: Volumes by CT and PET-CT in 13 Patients with 
Malignant Pleural Mesothelioma.
Volume, cc CT PET-CT P Value
GTV
Mean ± S.D. 788.9 ± 845.1 441.4 ± 420.0 0.01
Min-max (101.4 - 3352.1) (38.5 - 1250.2)
CTV
Mean ± S.D. 2040.6 ± 1360.5 1533.1 ± 1483.6 0.002
Min-max (479.6 - 5615.8) (254.4 - 5615.82)
PTV1
Mean ± S.D. 3824.7 ± 1777.7 2936.7 ± 1940.1 0.003
Min-max (1062.5 - 7523.8) (608.9 - 6971.9)
PTV2
Mean ± S.D. 2385.5 ± 1449.9 1627.9 ± 1254.2 0.003
Min-max (488.2 - 5853.1) (278.9 - 4088.4)
*Abbreviations: CT = computed tomography; CTV = clinical target 
volume; GTV = gross tumor volume; PET-CT = positron emission 
tomography-computed tomography; PTV1 = planning target volume 1 
(defined as CTV plus a 1-cm margin); PTV2 = planning target volume 
2 (defined as GTV plus a 1-cm margin).Page 4 of 7
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Linden et al treated 47 MPM patients with a dose of 40 Gy
in 20 fractions with and without chemotherapy and they
informed that all of patients experienced radiation
induced pulmonary fibrosis [29]. However, in this setting,
more sophisticated RT techniques such as IMRT, IGRT,
and especially helical-slit IMRT (HT) and cone-beam
IMRT (RapidArc and VMAT) [30] might become appropri-
ate alternatives for either definitive or palliative treatment
for suitable patients based on compatible pulmonary tox-
icity criteria. Helical tomotherapy is a promising method,
and achieves a better dose conformity in several tumor
sites including MPM [31-33]. In their recent study, Ster-
zing et al compared step-and-shoot IMRT with HT [33].
They observed that while both modalities achieved excel-
lent dose distributions, target coverage and homogenity
could be increased significantly with HT, additionally
contralateral lung dose could be lowered beyond 5 Gy.
They concluded that HT is an excellent option for the
IMRT of MPM. In our current study, as aforementioned it
was impossible to create appropriate RTPs and guiding
DVHs in absence of further technical advances such as HT
oppurtunities, yet, we believe that the significant reduc-
tions observed in target volumes, additional subdiaphrag-
matic extension and involved lymph nodes shown only
Representative image of a patient with CT- and PET- CT based GTV delineations; (a) axial CT (b) axial PET-CT, (c) coronal CT, (d) coronal PET-CTFigure 1
Representative image of a patient with CT- and PET- CT based GTV delineations; (a) axial CT (b) axial PET-
CT, (c) coronal CT, (d) coronal PET-CT. *Abbreviations: GTV = gross tumor volume; CT = computed tomography; PET-
CT = positron emission tomography-computed tomography.Page 5 of 7
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future studies with appropriate technologies.
Although CT is the primary imaging modality for both
staging and RTP in patients with MPM, the results of CT
fail to identify the true extent of local invasion through
the extrathoracic fascia, diaphragmatic surfaces, and inter-
lobar fissures. Results of CT cannot accurately distinguish
between malignant and benign conditions, such as
inflammation and pleural fluid, which are common find-
ings of MPM. Webb et al showed that the desmoplastic
reaction caused by tumor-induced proliferation of benign
connective tissue adjacent to the tumor can result in an
overestimation of the stage of the tumor [34]. Addition-
ally, CT has poor sensitivity for defining the malignant
status of mediastinal lymph nodes [8,9]. Earlier studies in
lung cancer showed significant changes when PET infor-
mation was applied, with decreased volumes mostly
attributed to exclusion of atelectasis [15,35-37]. We found
that 18-fluorodeoxyglucose PET led to better definition of
target volumes with additional metabolic information,
and it was more successful in discriminating between
tumor and benign connective tissue changes.
The additional volume and intratumoral functional varia-
tions uniquely identified by PET may be even more
important in the near future when so-called dose-painting
intensity-modulated radiotherapy becomes widely used
in clinical practice, opening the possibility of controlled
and reproducible internal-dose escalation to functionally
important areas of the tumor. With the use of more spe-
cific functional PET tracers, this high-precision RT tech-
nique could help enormously in resolving the problems
of overestimation and underestimation of GTV and miti-
gate their negative consequences for radiation manage-
ment of tumors at many sites, including MPM.
We believe that our current study might be a significant
contribution to the emerging RT literature regarding the
use of PET-CT data in conjunction with CT in RTP of MPM
patients. However, it is not appropriate to draw strict con-
clusions based on the current results without conforma-
tion of its use with novel sophisticated RT techniques such
as HT with dose- volume histogram data which can pre-
dict RT related toxicity after curative or palliative RT.
Therefore the present study seems to be a baseline data for
further clinical and dosimetric studies rather than being
considered as a guide.
Conclusion
This study demonstrated the usefulness of PET/CT based
target volume delineation in patients with MPM. The larg-
est potential benefit of incorporating PET into RTP for
MPM may be the reduction in geographic misses associ-
ated with CT-based planning, and, as a result, the poten-
tial reduction in local and regional treatment failures.
However, we believe that before reaching more definite
conclusions, more clinical studies are required to better
define the role of PET-CT fusion in this setting.
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